BACKGROUND: It is unclear if higher-dose oseltamivir provides benefit beyond the standard dose in influenza patients who require hospitalization. METHODS: A prospective intervention study was performed in 2 acute care general hospitals in Hong Kong over 4 seasonal peaks (2010-2012). Adults (≥18 years) with laboratory-confirmed influenza (85 A/H3N2, 34 A/H1N1pdm09, 36 B) infections who presented within 96 hours were recruited. Study regimen of either 150 mg or 75 mg oseltamivir twice daily for 5 days was allocated by site, which was switched after 2 seasons. Subjects with preexisting renal impairment (creatinine clearance, 40-60 mL/minute) received 75 mg oseltamivir twice daily. Viral clearance by day 5 and clinical responses were compared between groups. Plasma steady-state trough oseltamivir carboxylate (OC) concentration was measured by high-performance liquid chromatography-tandem mass spectrometry. RESULTS: Altogether, 41 and 114 patients received 150 mg and 75 mg twice-daily oseltamivir, respectively; their enrollment characteristics (mean age, 61 ± 18vs 66 ± 16 years) and illness severity were comparable. Trough OC levels were higher in the 150-mg group (501.0 ± 237.0 vs 342.6 ± 192.7 ng/mL). There were no significant differences in day 5 viral RNA (44.7% vs 40.2%) or culture negativity (100.0% vs 98.1%), RNA decline rate, and durations of fever, oxygen supplementation, and hospitalization. Results were similar when analyzed by study arm (all cases and among those without renal impairment). Subanalysis of influenza B patients showed faster RNA decline rate (analysis of variance, F = 4.14; P = .05) and clearance (day 5, 80.0% vs 57.1%) with higher-dose treatment. No oseltamivir resistance was found. Treatments were generally well tolerated. CONCLUSIONS: We found no additional benefit of higher-dose oseltamivir treatment in adults hospitalized with influenza A, but an improved virologic response in influenza B. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov, NCT01052961.
RCT Entities:
BACKGROUND: It is unclear if higher-dose oseltamivir provides benefit beyond the standard dose in influenza patients who require hospitalization. METHODS: A prospective intervention study was performed in 2 acute care general hospitals in Hong Kong over 4 seasonal peaks (2010-2012). Adults (≥18 years) with laboratory-confirmed influenza (85 A/H3N2, 34 A/H1N1pdm09, 36 B) infections who presented within 96 hours were recruited. Study regimen of either 150 mg or 75 mg oseltamivir twice daily for 5 days was allocated by site, which was switched after 2 seasons. Subjects with preexisting renal impairment (creatinine clearance, 40-60 mL/minute) received 75 mg oseltamivir twice daily. Viral clearance by day 5 and clinical responses were compared between groups. Plasma steady-state trough oseltamivir carboxylate (OC) concentration was measured by high-performance liquid chromatography-tandem mass spectrometry. RESULTS: Altogether, 41 and 114 patients received 150 mg and 75 mg twice-daily oseltamivir, respectively; their enrollment characteristics (mean age, 61 ± 18 vs 66 ± 16 years) and illness severity were comparable. Trough OC levels were higher in the 150-mg group (501.0 ± 237.0 vs 342.6 ± 192.7 ng/mL). There were no significant differences in day 5 viral RNA (44.7% vs 40.2%) or culture negativity (100.0% vs 98.1%), RNA decline rate, and durations of fever, oxygen supplementation, and hospitalization. Results were similar when analyzed by study arm (all cases and among those without renal impairment). Subanalysis of influenza B patients showed faster RNA decline rate (analysis of variance, F = 4.14; P = .05) and clearance (day 5, 80.0% vs 57.1%) with higher-dose treatment. No oseltamivir resistance was found. Treatments were generally well tolerated. CONCLUSIONS: We found no additional benefit of higher-dose oseltamivir treatment in adults hospitalized with influenza A, but an improved virologic response in influenza B. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov, NCT01052961.
Entities:
Keywords:
high dose; influenza; oseltamivir; treatment; viral clearance
Authors: Sarah C Welch; Simon W Lam; Elizabeth A Neuner; Seth R Bauer; Stephanie N Bass Journal: Intensive Care Med Date: 2015-05-08 Impact factor: 17.440
Authors: Mohamed A Kamal; Patrick F Smith; Nathorn Chaiyakunapruk; David B C Wu; Chayanin Pratoomsoot; Kenneth K C Lee; Huey Yi Chong; Richard E Nelson; Keith Nieforth; Georgina Dall; Stephen Toovey; David C M Kong; Aaron Kamauu; Carl M Kirkpatrick; Craig R Rayner Journal: Br J Clin Pharmacol Date: 2017-02-20 Impact factor: 4.335
Authors: Philippe Noriel Q Pascua; Jeremy C Jones; Bindumadhav M Marathe; Patrick Seiler; William V Caufield; Burgess B Freeman; Richard J Webby; Elena A Govorkova Journal: Antimicrob Agents Chemother Date: 2021-08-23 Impact factor: 5.191
Authors: Bindumadhav M Marathe; Heba H Mostafa; Peter Vogel; Philippe Noriel Q Pascua; Jeremy C Jones; Charles J Russell; Richard J Webby; Elena A Govorkova Journal: Antiviral Res Date: 2017-10-31 Impact factor: 5.970
Authors: Won Suk Choi; Ji Hyeon Baek; Yu Bin Seo; Sae Yoon Kee; Hye Won Jeong; Hee Young Lee; Byung Wook Eun; Eun Ju Choo; Jacob Lee; Young Keun Kim; Joon Young Song; Seong-Heon Wie; Jin Soo Lee; Hee Jin Cheong; Woo Joo Kim Journal: Korean J Intern Med Date: 2014-01-02 Impact factor: 2.884